home / stock / xair / xair news

XAIR News and Press, Beyond Air Inc. From 05/17/22

Stock Information
Company Name: Beyond Air Inc.
Stock Symbol: XAIR
Market: NASDAQ
Website: beyondair.net
Menu
XAIR XAIR Quote XAIR Short XAIR News XAIR Articles XAIR Message Board
Get XAIR Alerts

News, Short Squeeze, Breakout and More Instantly...
XAIR - Beyond Air® Presents Positive Study Update from the At-Home LungFit® GO Pilot Study for Nontuberculous Mycobacterial Lung Disease at the American Thoracic Society International Conference 2022

A total of 2,323 inhalations have been self-administered at home to date with no treatment related discontinuations reported and overall high treatment compliance All subjects have successfully titrated to receive the target 250 ppm NO regimen at home LungFit® GO is...
XAIR - Beyond Cancer, Ltd. Appoints Susan Howell Jones, CPA as Chief Financial Officer

HAMILTON, Bermuda, May 17, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced the appointment of Susan Howell Jones, CPA as...

XAIR - Beyond Air® Schedules Fiscal Year 2022 Financial Results Conference Call and Webcast

GARDEN CITY, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and...

XAIR - Beyond Air® Reports Positive Long-Term Safety Data for High Concentration Inhaled Nitric Oxide in Bronchiolitis at the Pediatric Academic Societies Meeting 2022

GARDEN CITY, N.Y., April 25, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections a...
XAIR - XAIR stock gains on data supporting inhaled nitric oxide as a COVID-19 therapy

Beyond Air (XAIR) has recorded the biggest intraday gain since November, after the clinical-stage health equipment company announced data from its LungFit PRO pilot study for inhaled nitric oxide in community-acquired viral pneumonia (CAVP), including COVID-19. Beyond Air (XAIR) is advancing ...

XAIR - Beyond Air® Presents Positive Safety and Efficacy Data for Inhaled Nitric Oxide to Treat COVID-19 at ECCMID 2022

Inhaled NO treatment in patients hospitalized with COVID-19 and other community-acquired viral pneumonia was well tolerated overall, and safe, with improved efficacy parameters as compared to standard supportive treatment Duration of oxygen support was significantly shorter for ...

XAIR - Beyond Air® to Participate in Three Upcoming Medical Conferences

GARDEN CITY, N.Y., April 18, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections a...
XAIR - Beyond Cancer(TM) Announces New Preclinical Data Presented at American Association for Cancer Research (AACR) Showing Ultra-High Concentration Nitric Oxide Therapy Anti-Tumor Effect

Data suggests ultra-high concentration gaseous NO (gNO) induced both innate and adaptive immune cell populations, and a decline in immune suppressor cells, which are indicative of an anti-tumor immune response Supports the hypothesis for the observed rejection of secondary tumor...

XAIR - Beyond Cancer(TM) to Present Two Abstracts for Ultra-High Concentration Nitric Oxide Therapy at the 2022 AACR Annual Meeting

GARDEN CITY, N.Y., March 08, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections a...

XAIR - GFI, CNR and XAIR among pre market gainers

BioDelivery Sciences International BDSI +51% Collegium Pharmaceutical to acquire BioDelivery Sciences for $5.60/share in all cash deal. Cornerstone Building Brands (NYSE:CNR) +22% CD&R makes non-binding proposal to acquire cornerstone building brands. Splunk SPLK +9%&#...
Previous 10 Next 10